Infections, Female Reproductive System DRG Reimbursement Guide

DRG 759 addresses inpatient admissions for infections of the female reproductive system without a Complication or Comorbidity or a Major Complication or Comorbidity, focusing on cases of lower severity. It matters for inpatient reimbursement because grouping influences the Medicare Severity Diagnosis-Related Group payment and thus hospital revenue for these episodes of care.

DRG 759 Overview

DRG 759 covers inpatient admissions for infections of the female reproductive system that do not carry a Complication or Comorbidity or a Major Complication or Comorbidity. Typical cases include pelvic inflammatory disease and other gynecologic infections treated medically or with minor procedures. This Diagnosis-Related Group matters for Medicare payment because it groups similar clinical severity into a single payment weight that affects hospital reimbursement for these admissions. Accurate coding of principal diagnosis and any secondary diagnoses determines assignment to this Diagnosis-Related Group and the associated Medicare Severity Diagnosis-Related Group payment.

DRG 759 Overview

Acute antimicrobial optimization trials: studies testing protocols to shorten time-to-appropriate therapy, compare empiric antibiotic regimens, or evaluate rapid diagnostic-guided escalation/de-escalation strategies in hospitalized women with pelvic inflammatory disease, tubo-ovarian abscess, endometritis, or other reproductive tract infections without major comorbidities. These trials enroll adult reproductive‑age and peri‑menopausal women admitted for acute infection and measure time to clinical resolution, length of stay, and antibiotic exposure; they are relevant because faster, targeted therapy can reduce complications, inpatient days, and antimicrobial costs. Providers and payers benefit from evidence that supports safe, resource‑efficient in-hospital management pathways and stewardship that lower readmission and resistance costs.
Comparative effectiveness studies of interventional vs. conservative management for localized abscesses: prospective cohort or randomized studies comparing percutaneous or transvaginal drainage plus antibiotics versus antibiotics alone for small to moderate adnexal or tubo‑ovarian abscesses in women without severe systemic disease. The population includes hospitalized patients whose infections meet imaging criteria for abscess but lack major organ dysfunction, assessing outcomes such as treatment failure, need for surgery, hospital length of stay, and post-discharge complications. This research informs decisions about procedural utilization, potential avoidance of operative interventions, and cost-effectiveness relevant to inpatient resource allocation and reimbursement under this DRG.
Post-discharge outcomes and quality-of-care studies: observational or pragmatic trials evaluating follow‑up strategies, patient education, and outpatient care coordination to prevent recurrence and readmission among women discharged after treatment for reproductive tract infections. These studies track adherence to follow‑up, rates of recurrent infection, fertility-related outcomes, and total episodic cost of care across 30–90 days, targeting patients without CC/MCC to identify gaps between inpatient treatment and outpatient recovery. Findings are important to payers and hospitals aiming to reduce readmissions, improve long‑term reproductive health outcomes, and align discharge planning with value-based reimbursement models.

Acute antimicrobial optimization trials: studies testing protocols to shorten time-to-appropriate therapy, compare empiric antibiotic regimens, or evaluate rapid diagnostic-guided escalation/de-escalation strategies in hospitalized women with pelvic inflammatory disease, tubo-ovarian abscess, endometritis, or other reproductive tract infections without major comorbidities. These trials enroll adult reproductive‑age and peri‑menopausal women admitted for acute infection and measure time to clinical resolution, length of stay, and antibiotic exposure; they are relevant because faster, targeted therapy can reduce complications, inpatient days, and antimicrobial costs. Providers and payers benefit from evidence that supports safe, resource‑efficient in-hospital management pathways and stewardship that lower readmission and resistance costs.
Comparative effectiveness studies of interventional vs. conservative management for localized abscesses: prospective cohort or randomized studies comparing percutaneous or transvaginal drainage plus antibiotics versus antibiotics alone for small to moderate adnexal or tubo‑ovarian abscesses in women without severe systemic disease. The population includes hospitalized patients whose infections meet imaging criteria for abscess but lack major organ dysfunction, assessing outcomes such as treatment failure, need for surgery, hospital length of stay, and post-discharge complications. This research informs decisions about procedural utilization, potential avoidance of operative interventions, and cost-effectiveness relevant to inpatient resource allocation and reimbursement under this DRG.
Post-discharge outcomes and quality-of-care studies: observational or pragmatic trials evaluating follow‑up strategies, patient education, and outpatient care coordination to prevent recurrence and readmission among women discharged after treatment for reproductive tract infections. These studies track adherence to follow‑up, rates of recurrent infection, fertility-related outcomes, and total episodic cost of care across 30–90 days, targeting patients without CC/MCC to identify gaps between inpatient treatment and outpatient recovery. Findings are important to payers and hospitals aiming to reduce readmissions, improve long‑term reproductive health outcomes, and align discharge planning with value-based reimbursement models.

OpenPayer

Infections, Female Reproductive System without CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 759 policy alerts

DRG 759 Overview

OpenPayer

Infections, Female Reproductive System without CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 759 policy alerts

DRG 759 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References